Amiglyde-V (Canada)This page contains information on Amiglyde-V for veterinary use.
The information provided typically includes the following:
- Amiglyde-V Indications
- Warnings and cautions for Amiglyde-V
- Direction and dosage information for Amiglyde-V
Amiglyde-VThis treatment applies to the following species:
AMIKACIN SULFATE, USP
VETERINARY USE ONLY
Amikacin sulfate is a semi-synthetic aminoglycoside antibiotic derived from kanamycin. It is C22H43N5O13 • 2H2SO4, D-streptamine, 0 - 3 - amino - 3 - deoxy - α - D - glucopyranosyl - (1®6) - 0 - [6 - amino - 6 - deoxy - α - D - glucopyranosyl - (1®4)] - N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-, sulfate (1:2) (salt).
The dosage form supplied is a sterile, colourless to light straw-coloured solution. The solution contains, in addition to amikacin sulfate, 2.5% sodium citrate, USP with pH adjusted to 4.5 with sulfuric acid and 0.66% sodium bisulfite added. The multi-dose 12 gram-48 mL vial contains 0.01% benzethonium chloride, USP as a preservative.
The effectiveness of AMIGLYDE-V (amikacin sulfate) in infections caused by Escherichia coli, Pseudomonas sp and Klebsiella sp has been demonstrated clinically in the horse. In addition, the following microorganisms have been shown to be susceptible to amikacin in vitro1, although the clinical significance of this action has not been demonstrated in animals: Enterobacter sp, Proteus mirabilis, Proteus sp (indole positive), Serratia marcescens, Salmonella sp, Shigella sp, Providencia sp, Citrobacter freundii, Listeria monocytogenes, Staphylococcus aureus (both penicillin resistant and penicillin-sensitive)
The aminoglycoside antibiotics in general have limited activity against gram-positive pathogens, although Staphylococcus aureus and Listeria monocytogenes are susceptible to amikacin as noted above.
Amikacin has been shown to be effective against many aminoglycoside-resistant strains due to its ability to resist degradation by aminoglycoside inactivating enzymes known to affect gentamicin, tobramycin and kanamycin2.
Endometrial Tissue Concentrations
Comparisons of amikacin activity in endometrial biopsy tissue following intrauterine infusion with that following intramuscular injection of AMIGLYDE-V in mares demonstrate superior endometrial tissue concentrations when the drug is administered by the intrauterine route.
Intrauterine infusion of 2 grams of AMIGLYDE-V daily for three consecutive days in mares results in peak concentrations typically exceeding 40 mcg/g of endometrial biopsy tissue within one hour after infusion. Twenty-four hours after each treatment amikacin activity is still detectable at concentrations averaging 2 to 4 mcg/g. However, the drug is not appreciably absorbed systemically following intra-uterine infusion. Endometrial tissue concentrations following intramuscular injection roughly parallel, but are typically somewhat lower than corresponding serum concentrations of amikacin.
AMIGLYDE-V is non-irritating to equine endometrial tissue when infused into the uterus as directed (see ADMINISTRATION AND DOSAGE). In laboratory animals as well as in equine studies, the drug was generally found not to be irritating when injected intravenously, subcutaneously or intramuscularly.
Although amikacin, like other aminoglycosides, is potentially nephrotoxic, ototoxic and neurotoxic, parenteral (intravenous) administration of AMIGLYDE-V (amikacin sulfate) twice daily at dosages of up to 22 mg/kg for 15 consecutive days in horses resulted in no clinical, laboratory or histopathologic evidence of toxicity.
Studies in vitro have shown that amikacin is not spermicidal when added to stallion or bull semen extender at concentrations of as high as 1,000 mcg/mL. In reproductive studies, all mares artificially inseminated with extended semen containing AMIGLYDE-V at a concentration of 100 mcg/mL became pregnant. Intrauterine infusion of 2 grams of AMIGLYDE-V 8 hours prior to breeding by natural service did not impair fertility in mares. Therefore, mares should not be bred for at least 8 hours following uterine infusion.
AMIGLYDE-V is indicated for the treatment of uterine infections (endometritis, metritis and pyometra) in mares, when caused by susceptible organisms including Escherichia coli, Pseudomonas sp and Klebsiella sp. The use of AMIGLYDE-V in eliminating infections caused by the above organisms has been shown clinically to improve fertility in infected mares.
While nearly all strains of Escherichia coli, Pseudomonas sp and Klebsiella sp, including those that are resistant to gentamicin, kanamycin or other aminoglycosides, are susceptible to amikacin at levels achieved following treatment, it is recommended that the invading organism be cultured and its susceptibility demonstrated as a guide to therapy. Amikacin susceptibility discs, 30 mcg, should be used for determining in vitro susceptibility.
There are no known contraindications for the use of AMIGLYDE-V in horses other than a history of hypersensitivity to amikacin.
Although AMIGLYDE-V is not absorbed to an appreciable extent following intrauterine infusion, concurrent use of other aminoglycosides should be avoided because of the potential for additive effects.
In vitro studies have demonstrated that when sperm are exposed to the preservative which is present in the 48 mL vials (250 mg/mL) sperm viability is impaired.
Administration And Dosage
For treatment of uterine infections in mares, 2 grams (8 mL) of AMIGLYDE-V, mixed with 200 mL 0.9% Sodium chloride injection, USP and aseptically infused into the uterus daily for three consecutive days, has been found to be the most efficacious dosage.
No adverse reactions or other side effects have been reported.
This drug is not to be administered to horses that are to be slaughtered for use in food.
AMIGLYDE-V (amikacin sulfate) Veterinary Solution is supplied as a colourless solution which is stable at room temperature. At times the solution may become pale yellow in colour. This does not indicate a decrease in potency.
48 mL vial, 250 mg/mL
Store at controlled room temperature 15° to 30°C.
1. Price, K.E., et al: Microbiological Evaluation of BB-K8, a New Semisynthetic Aminoglycoside. J. Antibiot. 25: 709-731, 1972.
2. Davies, J., Courvalin, P.: Mechanisms of Resistance to Aminoglycosides. Am J Med 62: 868-872, 1977.
Wyeth Animal Health, Division of Wyeth Canada, Guelph, Ontario N1K 1E4
® Licensed user of Amiglyde-V
NAC No.: 11983591
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the Amiglyde-V information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2015 North American Compendiums. Updated: 2015-11-23